Imperial College London

Dr Benjamin Mullish

Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

NIHR Clinical Lecturer
 
 
 
//

Contact

 

b.mullish

 
 
//

Location

 

Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Publication Type
Year
to

262 results found

Ghani R, Mullish BH, Roberts LA, Davies FJ, Marchesi JRet al., 2022, The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases, Gut Microbes, Vol: 14, ISSN: 1949-0976

Journal article

Powles STR, Gallagher KI, Chong LWL, Alexander JL, Mullish BH, Hicks LC, McDonald JAK, Marchesi JR, Williams HRT, Orchard TRet al., 2022, Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome, BMC Gastroenterology, Vol: 22

<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Urinary and faecal metabolic profiling have been extensively studied in gastrointestinal diseases as potential diagnostic markers, and to enhance our understanding of the intestinal microbiome in the pathogenesis these conditions. The impact of bowel cleansing on the microbiome has been investigated in several studies, but limited to just one study on the faecal metabolome.</jats:p> </jats:sec><jats:sec> <jats:title>Aim</jats:title> <jats:p>To compare the effects of bowel cleansing on the composition of the faecal microbiome, and the urine and faecal metabolome.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Urine and faecal samples were obtained from eleven patients undergoing colonoscopy at baseline, and then at day 3 and week 6 after colonoscopy. 16S rRNA gene sequencing was used to analyse changes in the microbiome, and metabonomic analysis was performed using proton nuclear magnetic resonance (<jats:sup>1</jats:sup>H NMR) spectroscopy.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Microbiomic analysis demonstrated a reduction in alpha diversity (Shannon index) between samples taken at baseline and three days following bowel cleansing (<jats:italic>p</jats:italic> = 0.002), and there was no significant difference between samples at baseline and six weeks post colonoscopy. Targeted and non-targeted analysis of urinary and faecal bacterial associated metabolites showed no significant impact following bowel cleansing.</jats:p> </jats:sec><jats:sec>

Journal article

Mullish BH, Martinez Gili L, Chekmeneva E, Dos Santos Correia GDS, Lewis MR, Horneffer-van der Sluis V, Roberts LA, McDonald JAK, Pechlivanis A, Walters JRF, McClure EL, Marchesi JR, Allegretti JRet al., 2022, Assessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection, Alimentary Pharmacology and Therapeutics, ISSN: 0269-2813

Journal article

Wang D, Durainayagam B, Forlano R, Qi Z, Mullish B, Huang J, Manousou P, Thursz M, Griffin Jet al., 2022, Lipid profiling of extracellular vesicles and plasma in people with non-alcoholic fatty liver disease, EASL NAFLD Summit 2022, Publisher: EASL

Conference paper

Wang D, Durainayagam B, Forlano R, Zhong Q, Huang J, Mullish B, Manousou P, Thursz M, Griffin Jet al., 2022, Phosphatidylcholines (36:1) and (36:3) are increased in postmenopausal women with NAFLD, EASL NAFLD summit 2022

Conference paper

Huang J, Forlano R, Wang D, Guerra N, Jenkins B, Mullish B, Thursz M, Sharma R, Manousou Pet al., 2022, Anti-pd-1 treatment affects lipidomic profile in an animal model of NAFLD-HCC, EASL NAFLD summit 2022

Conference paper

Huang J, Forlano R, Wang D, Guerra N, Jenkins B, Mullish B, Thursz M, Sharma R, Manousou Pet al., 2022, A specific lipidomic fingerprint is associated with the development of nalfd-associated hcc in an animal model, EASL NAFLD summit 2022

Conference paper

Smith PJ, 2022, GI highlights from the literature, Gut, Vol: 71, Pages: 1916-1917, ISSN: 0017-5749

Journal article

MiguensBlanco J, Mullish BH, 2022, New insights into host‐microbiome crosstalk in psoriatic skin, Clinical and Translational Discovery, Vol: 2, ISSN: 2768-0622

Journal article

Ianiro G, Mullish BH, Iqbal TH, Terveer EM, Baunwall SMD, Link A, Sokol H, Kupcinskas J, Masucci L, Sanguinetti M, Vehreschild MJGT, Hvas CL, Keller JJ, Gasbarrini A, Kujiper EJ, Cammarota Get al., 2022, Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel, The Lancet Gastroenterology &amp; Hepatology, ISSN: 2468-1253

Journal article

Lythgoe MP, Mullish BH, Frampton AE, Krell Jet al., 2022, Polymorphic microbes: a new emerging hallmark of cancer, Trends in Microbiology, ISSN: 0966-842X

Journal article

Shawcross DL, Halilbasic E, Mullish BH, Chokshi S, Skinner C, Bajaj JS, Shen Yet al., 2022, Recent Findings in the Gut-Liver Axis and Associated Disease Therapy, EMJ Hepatology, Vol: 10 Supplement 3, Pages: 4-16

Journal article

Mullish BH, 2022, National clinical expert consensus statement: Coronavirus monoclonal antibodies as a prophylactic therapy against COVID-19 for immunocompromised groups

- Novel long-acting coronavirus prophylactic monoclonal antibodytherapies have been shown to be effective in preventing COVID19 in immunocompromised individuals who are at increased riskfrom SARS-CoV-2.- Prophylactic antibody therapies should be made available in atimely manner to give an antibody immunity boost to vulnerablepatients.- Real world evaluations should be co-implemented to provideconfidence of ongoing effectiveness.- Successful delivery of a coronavirus prophylactic antibodytherapy programme would deliver significant benefits tohealthcare systems, communities and immunocompromisedindividuals.

Report

Forlano R, Sivakumar M, Mullish BH, Manousou Pet al., 2022, Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review, International Journal of Molecular Sciences, Vol: 23, Pages: 8307-8307

<jats:p>Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease, affecting one-third of the population worldwide. Despite many medications being in the pipeline to treat the condition, there is still no pharmaceutical agent licensed to treat the disease. As intestinal bacteria play a crucial role in the pathogenesis and progression of liver damage in patients with NAFLD, it has been suggested that manipulating the microbiome may represent a therapeutical option. In this review, we summarise the latest evidence supporting the manipulation of the intestinal microbiome as a potential therapy for treating liver disease in patients with NAFLD.</jats:p>

Journal article

Moore-Gillon C, Cole A, Bashyam M, Vithayathil M, Nathwani R, Koeckerling D, Mukherjee S, Mullish BH, Lemoine M, Possamai L, Lewis H, Selvapatt N, Dhar Aet al., 2022, A study evaluating outcomes of a virtual specialist liver cirrhosis clinic, JOURNAL OF HEPATOLOGY, Vol: 77, Pages: S345-S346, ISSN: 0168-8278

Journal article

Marjot T, Murray S, Pose E, Lim Z, Carlota Londono M, Wittner M, Luetgehetmann M, Hernandez-Gea V, Garcia Pagan JC, Schaub G, Duengelhoef P, Sterneck M, Lohse AW, Trivedi P, Bhandal K, Mullish BH, Manousou P, Burra P, Facchetti F, Dobson SL, Deeks AS, Turtle L, Klenerman P, Dunachie S, Gines P, Iavarone M, Schulze zur Wiesch J, Paolo Russo F, Barnes Eet al., 2022, Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study, JOURNAL OF HEPATOLOGY, Vol: 77, Pages: S54-S55, ISSN: 0168-8278

Journal article

Habboub N, Manousou P, Forlano R, Mullish BH, Frost G, Challis B, Thursz M, Dumas M-Eet al., 2022, Designing a polymetabolic risk score for non-alcoholic steatohepatitis patients by differentiating their metabolic profiles from healthy controls, JOURNAL OF HEPATOLOGY, Vol: 77, Pages: S179-S179, ISSN: 0168-8278

Journal article

Skinner C, Marchesi J, Mullish BH, Kudo H, Roberts L, Sun H, Forlano R, Lord E, Thursz M, Vergis Net al., 2022, Tight junction damage and increased gut permeability in alcohol-related liver disease may be mediated by gut proteases, JOURNAL OF HEPATOLOGY, Vol: 77, Pages: S121-S122, ISSN: 0168-8278

Journal article

Forlano R, Stanic T, Jayawardana S, Mullish BH, Yee M, Thursz M, Mossialos E, Manousou Pet al., 2022, Clinical and economic evaluation of community-based preventative screening strategies for non-alcoholic fatty liver disease in people with Type-2 diabetes melllitus, JOURNAL OF HEPATOLOGY, Vol: 77, Pages: S444-S444, ISSN: 0168-8278

Journal article

Forlano R, Mullish BH, Martinez-Gili L, Blanco JM, Liu T, Triantafyllou E, Skinner C, Thursz M, Marchesi J, Manousou Pet al., 2022, Factors associated with increased gut permeability and severity of liver disease in diabetic patients with NAFLD, JOURNAL OF HEPATOLOGY, Vol: 77, Pages: S674-S675, ISSN: 0168-8278

Journal article

Smith PJ, 2022, GI highlights from the literature, Gut, Vol: 71, Pages: 1440-1441, ISSN: 0017-5749

Journal article

Mullish BH, McDonald JAK, Marchesi JR, 2022, Intestinal microbiota transplantation: do not forget the metabolites, The Lancet Gastroenterology &amp; Hepatology, Vol: 7, Pages: 594-594, ISSN: 2468-1253

Journal article

Mullish BH, Martinez-Gili L, Chekmeneva E, Correia GDS, Lewis MR, Der Sluis VH-V, McDonald JAK, Pechlivanis A, Walters JRF, McClure EL, Marchesi JR, Allegretti JRet al., 2022, Fecal bile acid profiles predict recurrence in patients with primary <i>Clostridioides difficile</i> infection

<jats:label>1.</jats:label><jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Factors that influence recurrence risk in primary <jats:italic>Clostridioides difficile</jats:italic> infection (CDI) are poorly understood, and tools to predict recurrence are lacking. Perturbations in microbial-derived bile acids (BAs) contribute to CDI pathogenesis and may be relevant to primary disease prognosis.</jats:p></jats:sec><jats:sec><jats:title>Aims</jats:title><jats:p>To define stool bile acid profiles and microbial bile-metabolising functionality in primary CDI patients, and explore signatures predicting recurrence.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Weekly stool samples were collected from primary CDI patients from the last day of anti-CDI therapy until recurrence, or through eight weeks post-completion otherwise. Ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) was used to profile bile acids, and bacterial bile salt hydrolase (BSH) activity was measured to determine primary BA deconjugation capacity. Multivariate and univariate models were used to define differential BA trajectories in recurrers <jats:italic>versus</jats:italic> non-recurrers, and assess fecal bile acids as predictive markers for recurrence.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Twenty (36%) out of 56 patients (median age 57, 64% male) recurred, with 80% of recurrence occurring within the first nine days post-antibiotic treatment. Principal component analysis (PCA) of stool bile acid profiles demonstrated clustering of samples by recurrence status and post-treatment time point. Longitudinal fecal bile acid trajectories in non-recurrers showed a recovery of secondary bile acids and their derivatives in non-r

Journal article

Kearns P, Siebert S, willicombe M, Gaskell C, Kirkham A, Pirrie S, Bowden S, Magwaro S, Hughes A, Lim Z, Dimitriadis S, Murray S, Marjot T, Win Z, Irwin S, Meacham G, Richter A, Kelleher P, Satsangi J, Miller P, Rea D, Cook G, Turtle L, Klenerman P, Dunachie S, Basu N, Silva TD, Thomas D, Barnes E, Goodyear C, McInnes Iet al., 2022, Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity – the OCTAVE trial

SARS-COV-2 vaccines have been shown to be efficacious primarily in healthy volunteer populations and population level studies. Immune responses following SARS-CoV-2 vaccination are less well characterised in potentially immune vulnerable patient groups, including those with immune-mediated inflammatory and chronic diseases (inflammatory arthritis [IA] incorporating rheumatoid arthritis [RA] and psoriatic arthritis [PsA]; ANCA-Associated Vasculitis [AAV]; inflammatory bowel disease [IBD]); hepatic disease (HepD), end stage kidney disease requiring haemodialysis (HD) without or with immunosuppression (HDIS); solid cancers (SC) and haematological malignancies (HM), and those that have undergone haemopoietic stem cell transplant (HSCT). The OCTAVE trial is a multi-centre, multi-disease, prospective cohort that will comprehensively assess SARS-CoV-2 vaccine responses within and between the abovementioned disease cohorts using common analytical platforms in patients recruited across the United Kingdom (UK). The majority of subjects received either COVID-19 mRNA Vaccine BNT162b2 (Pfizer/BioNTech) or ChAdOx1 Vaccine (AstraZeneca formerly AZD1222) as part of the UK National COVID19 vaccination programme. As of 13 th August 2021; 2,583 patients have been recruited. We report herein the humoral and T cell immune response results from the first 600 participants recruited where serology data are available at baseline, pre-second vaccine dose (boost) and/or 4 weeks post second dose. We also include in the analysis, data obtained from 231 healthy individuals from the PITCH (Protective Immunity from T cells in Healthcare workers) study. Overall, in comparison to PITCH where 100% of tested individuals (n=93) generated anti-Spike antibodies after vaccine doses, 89% of patients within OCTAVE seroconverted 4 weeks after second vaccine dose. By corollary, approximately 11% of patients across all disease cohorts fail to generate antibodies that react to SARS-CoV-2 spike 4 weeks after t

Working paper

Alexander J, Mullish B, Danckert N, Liu Z, Saifuddin A, Torkizadeh M, Ibraheim H, Miguens-Blanco J, Bewshea C, Nice R, Lin S, Prabhudev H, Sands C, Lewis M, Teare J, Hart A, Kennedy N, Ahmad T, Marchesi J, Powell Net al., 2022, COVID-19 VACCINATION RESPONSE IN IMMUNOSUPPRESSED PATIENTS WITH IBD IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION, Publisher: BMJ PUBLISHING GROUP, Pages: A36-A36, ISSN: 0017-5749

Conference paper

Alexander JL, Mullish BH, Danckert NP, Liu Z, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Roberts LA, Bewshea CM, Nice R, Lin S, Prabhudev H, Sands C, Sluis VH-VD, Lewis M, Sebastian S, Lees CW, Teare JP, Hart A, Goodhand JR, Kennedy NA, Marchesi JR, Ahmad T, Powell Net al., 2022, The gut microbiota and metabolome is associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients

<jats:title>Abstract</jats:title> <jats:p>Patients with inflammatory bowel disease (IBD) treated with anti-TNF therapy exhibit attenuated humoral immune responses to vaccination against SARS-CoV-2. The gut microbiota and its functional metabolic output, which are perturbed in IBD, play an important role in shaping host immune responses. We explored whether the gut microbiota and metabolome could explain variation in anti-SARS-CoV-2 vaccination responses in immunosuppressed IBD patients. Faecal and serum samples were prospectively collected from infliximab-treated patients with IBD in the CLARITY-IBD study undergoing vaccination against SARS-CoV-2. Antibody responses were measured following two doses of either ChAdOx1 nCoV-19 or BNT162b2 vaccine. Patients were classified as having responses above or below the geometric mean of the wider CLARITY-IBD cohort. 16S rRNA gene amplicon sequencing, nuclear magnetic resonance (NMR) spectroscopy and bile acid profiling with ultra-high-performance liquid chromatography mass spectrometry (UHPLC-MS) were performed on faecal samples. Univariate, multivariable and correlation analyses were performed to determine gut microbial and metabolomic predictors of response to vaccination. Forty-three infliximab-treated patients with IBD were recruited (30 Crohn’s disease, 12 ulcerative colitis, 1 IBD-unclassified; 26 with concomitant thiopurine therapy). Eight patients had evidence of prior SARS-CoV-2 infection. Seventeen patients (39.5%) had a serological response below the geometric mean. Gut microbiota diversity was lower in below average responders (p = 0.021). <jats:italic>Bilophila</jats:italic> abundance was associated with better serological response, while <jats:italic>Streptococcus</jats:italic> was associated with poorer response. The faecal metabolome was distinct between above and below average responders (OPLS-DA R<jats:sup>2</jats:sup>X 0.25, R&l

Journal article

Zhang D, Mullish BH, Wang J, Barker G, Chrysostomou D, Gao S, Chen L, McDonald JAK, Marchesi JR, Cheng Let al., 2022, Identifying transient and stable bacteria- metabolite interactions from longitudinal multi-omics data, Publisher: Research Square Platform LLC

<jats:title>Abstract</jats:title> <jats:p>Background Understanding the complex relationships between bacteria and metabolites in ecological systems are extremely important in studies of different microbiomes. Longitudinal multi-omics study is adopted to investigate interactions between bacteria and metabolites, by directly associating their longitudinal profiles. Since a bacteria/metabolite may involve in many different biological processes, the longitudinal profile is an average of different interactions. Therefore, direct association could only uncover the strongest interactions.Results Here we present a computational approach that can rebuild short- and long-term bacteria-metabolite interactions from longitudinal multi-omics datasets. For this task, we re-analyse data (both microbial sequencing and metabolomic analysis) from an <jats:italic>in vitro</jats:italic> model of <jats:italic>Clostridioides difficile</jats:italic> infection and faecal microbiota transplant, a disease state and mode of therapy in which perturbed microbiome-metabolome interactions (and their reversal) are well-established to be pertinent. By analysing such a dataset, we generated both a short-term and a long-term interaction network, which predicted many new interactions. Four new interactions were randomly selected to be validated. In batch culture experiments, we validated two of them: (1) <jats:italic>Ruminococcus gnavus</jats:italic> and <jats:italic>Ruminococcus luti</jats:italic> could generate 3-ketocholanic acid (2) <jats:italic>Blautia obeum</jats:italic> could consume succinate.Conclusions The deconvolution of the raw longitudinal signal into short- and long-term trends can help users to gain a deeper understanding of their data. This tool will be useful for high-throughput screening of microbe/metabolite/host interactions from a longitudinal multi-omics setting.</jats:p>

Working paper

Forlano R, Stanic T, Jayawardana S, Mullish BH, Yee M, Thursz MR, Mossialos E, Manousou Pet al., 2022, CLINICAL AND ECONOMICAL EVALUATION OF COMMUNITY-BASED PREVENTATIVE SCREENING STRATEGIES FOR NON-ALCOHOLIC FATTY LIVER DISEASE, GASTROENTEROLOGY, Vol: 162, Pages: S1134-S1134, ISSN: 0016-5085

Journal article

Forlano R, Mullish BH, Martinez-Gili L, Blanco JM, Liu T, Triantafyllou E, Skinner C, Thursz MR, Marchesi J, Manousou Pet al., 2022, FACTORS ASSOCIATED WITH INCREASED GUT PERMEABILITY AND SEVERITY OF LIVER DISEASE IN DIABETIC PATIENTS WITH NAFLD, GASTROENTEROLOGY, Vol: 162, Pages: S1136-S1136, ISSN: 0016-5085

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00350833&limit=30&person=true